Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Combination therapy is becoming more and more general in the treatment of oncological
diseases. In this clinical trial combination the standard immunotherapeutic treatment; the
programmed death 1 (PD-1) regulatory antibody Nivolumab and a peptide vaccine consisting of
programmed death ligand 1 (PD-L1) and Indoleamine 2,3-dioxygenase (IDO) peptides will be
tested in patients with metastatic melanoma. Patients will be treated with Nivolumab every
second week as long as there is clinical benefit. The PD-L1/IDO peptide vaccine is given from
start of Nivolumab and every second week for the first 6 vaccines and thereafter every fourth
week up to 1 year.